Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.20 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 08/12/15 All times are local (Market data is delayed by at least 15 minutes).

puretech health plc (PTCHF) Snapshot

Open
$2.20
Previous Close
$2.20
Day High
$2.20
Day Low
$2.20
52 Week High
07/29/15 - $2.39
52 Week Low
08/12/15 - $2.20
Market Cap
522.3M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
237.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PURETECH HEALTH PLC (PTCHF)

Related News

No related news articles were found.

puretech health plc (PTCHF) Related Businessweek News

No Related Businessweek News Found

puretech health plc (PTCHF) Details

PureTech Health plc, a science-driven healthcare company, focuses on developing technologies that seek to address significant healthcare markets. The company, through its subsidiaries and operating companies, engages in developing microbiome immune system drug-discovery platform and drug candidates for the treatment of immune-mediated diseases; and products that seek to induce weight loss and potentially enhance glycaemic control through an orally administered capsule. It is also developing technology and products for the screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder; and combination therapy for the treatment of schizophrenia. In addition, the company is developing drug delivery platform for the oral administration of proteins, peptides, and other difficult-to-deliver payloads, including magnetic nanoparticles; and products to generate new human hair follicles and hair. Further, it is developing a platform and products that takes in physiological data from sensors and correlates that data with musical data components; voice-based tools for the passive assessment and tracking of patient health; commensal organism-based products for the improvement of human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as identifying healthcare expert networks and reviewing their conversations and content on social media. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.

61 Employees
Last Reported Date: 08/25/15
Founded in 2015

puretech health plc (PTCHF) Top Compensated Officers

Co-Founder, Chief Executive Officer and Execu...
Total Annual Compensation: $614.9K
Executive Vice President of Legal, Finance & ...
Total Annual Compensation: $410.4K
Compensation as of Fiscal Year 2014.

puretech health plc (PTCHF) Key Developments

PureTech Health plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

PureTech Health plc reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported revenue of $10,989,000 against $1,140,000 a year ago. The increase in revenue is primarily attributable to a $10.0 million non-refundable payment Vedanta Biosciences received as part of its collaboration with Janssen Biotech to develop and commercialise VE202, a microbiome product candidate. Operating loss was $11,606,000 against $4,918,000 a year ago. Loss before taxes was $15,475,000 against $32,837,000 a year ago. The $17.3 million decrease in the first half of 2015 results from a $6.7 million increase in operating loss offset by a decline of $24 million in net finance costs. Loss for the period was $17,234,000 against $32,837,000 a year ago. Net cash outflow from operating activities was $2,054,000 against $3,325,000 a year ago. Basic and diluted loss per share was $0.06 against $0.26 a year ago. Purchase of property and equipment was $2,247,000 against $67,000 a year ago. Loss attributable to owners of the company was $9,327,000 against $16,398,000 a year ago.

PureTech Health plc to Report First Half, 2015 Results on Aug 25, 2015

PureTech Health plc announced that they will report first half, 2015 results on Aug 25, 2015

PureTech Names Marko Ahtisaari as CEO

PureTech announced that it has named a former Nokia executive as its first CEO. Marko Ahtisaari, who served as head of design for the Nokia a few years back, was named to head the startup less than a year after it was launched. Ahtisaari, 45, left his position at Nokia in 2013 after four years, a job he came into after Nokia bought the company he previously co-founded and led, a social networking service called Dopplr. Now, he is a Director's Fellow at the MIT Media Lab.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTCHF:US $2.20 USD 0.00

PTCHF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTCHF.
View Industry Companies
 

Industry Analysis

PTCHF

Industry Average

Valuation PTCHF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.4x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PURETECH HEALTH PLC, please visit www.puretechhealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.